Piramal Pharma Expands and Upgrades UK Manufacturing Facilities

Piramal Pharma Solutions, a contract development and manufacturing organization (CDMO) and part of Piramal Pharma Limited, is expanding its antibody-drug conjugate (ADC) capabilities with the construction of a new facility in Grangemouth, Scotland, and is upgrading its active pharmaceutical ingredient (API) infrastructure at its existing facility in Morpeth, England. These expansions and upgrades together amount to a total investment of approximately $75 million. The investment is intended to enhance the CDMO’s UK-based drug development and manufacturing capabilities, and create new employment opportunities for technical and operational staff.

As for the ADC expansion, the first phase features the addition of two new ADC manufacturing suites, which are expected to be operational by Q3 of 2023. The building housing the suites was designed to accommodate further expansion, and future plans for expansion include the addition of a new sterile fill-finish suite dedicated to ADCs, as well as two additional large-scale manufacturing suites capable of handling increased batch sizes. In addition, a new customer experience center is being constructed for clients visiting the site during development and/or manufacturing activities.

When the expansion is completed, ADC capacity at the Grangemouth site will be significantly increased. The new facility will be fully supported by analytical laboratories, including quality control, cell-based assay and enzyme-linked immune sorbent assay, along with good manufacturing practice. The facility will also be supported by warehousing and administrative offices that will all be housed in a purpose-built facility.